Edit Module

Zoetis to Acquire Nexvet Veterinary Biologic Therapeutics Co.

The acquisition will strengthen Zoetis's portfolio of solutions for chronic pain management in dogs and cats.


Published:

Zoetis Inc. announced it will purchase Nexvet Biopharma veterinary biologic therapeutics company for US $6.72 per share, or a valuation of approximately US $85 million. Pending approval, the purchase is expected to be completed during the second half of 2017. According to Zoetis, headquartered in Parsippany, N.J., the acquisition will strengthen the company’s portfolio of solutions for chronic pain management in dogs and cats.

Nexvet, founded in 2010 and headquartered in Tullamore, Ireland, develops monoclonal antibody (mAb) therapies for companion animals in pain and other therapeutic areas. The company has research and development operations in Melbourne, Australia, a manufacturing facility in Tullamore, and an office in San Francisco.

Nexvet’s pipeline product ranevetmab, an mAb targeting nerve-growth factor for treatment of chronic pain associated with osteoarthritis in dogs, would, upon approval, be the companion animal industry’s first monoclonal antibody therapy administered monthly by injection for chronic pain.

Nexvet is also developing frunevetmab, a monoclonal antibody targeting NGF to treat chronic pain associated with osteoarthritis in cats.

Zoetis’ mAb therapy Cytopoint was licensed in the U.S. in December to control the clinical signs such as itching associated with atopic dermatitis in dogs. The company anticipates its approval in the European Union this year.

Edit Module
Edit ModuleShow Tags

Archive »Read More

Surgical Program for Vet Interns Helps Shelter Pets

Veterinary Speciality Center in Buffalo Grove, Ill., launched Shelter Animal Surgical Service to help shelter pets who need surgical procedures.

Study Reveals Ways to Determine Surgical Margins for Feline Tumors

Research from Oregon State University can help surgeons avoid removing noncancerous tissues in cats with feline injection-site sarcoma.

Researchers Repair Nonunion Fractions With Bone Regrowth Tech

Orthopedic surgeons at UC Davis utilized the technology to help repair bone injuries in dogs.
Edit Module
Edit Module
Edit ModuleEdit ModuleShow Tags Edit Module
Edit Module Edit Module
Edit ModuleShow Tags

Events


Show More...
Edit Module
Edit Module